GlassScriptPhysician profile
Mark G Campbell
NPI 1851392948
$5,524.51
in general payments reported to CMS, 2019-2025
49 companies · $20.02 in 2025
The $20.02 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,149 · 2020: $439 · 2021: $136 · 2022: $1,427 · 2023: $956 · 2024: $398 · 2025: $20.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.36 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $469.14 | 2019-2024 | Enhertu, Calquence, Lynparza |
| Amgen INC. | $371.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $361.23 | 2019-2025 | |
| Genentech USA, INC. | $346.21 | 2019-2024 | Venclexta |
| Pfizer INC. | $314.66 | 2019-2024 | |
| Eisai INC. | $300.98 | 2019-2024 | |
| Janssen Biotech, INC. | $262.03 | 2019-2024 | Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $248.73 | 2019-2023 | Lynparza, Keytruda |
| Celgene Corporation | $192.88 | 2019-2024 | Reblozyl, Pomalyst |
| Emd Serono, INC. | $187.93 | 2019-2024 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $183.45 | 2019-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $174.81 | 2019-2024 | Xtandi, Padcev |
| Ipsen Biopharmaceuticals, INC | $160.64 | 2019-2023 | Tazverik |
| Genzyme Corporation | $137.70 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.83 | 2019-2023 | Alunbrig |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.